Literature DB >> 2159438

Detection of a soluble form of the CD30 antigen in sera of patients with lymphoma, adult T-cell leukemia and infectious mononucleosis.

M Pfreundschuh1, C Pohl, C Berenbeck, J Schroeder, W Jung, R Schmits, A Tschiersch, V Diehl, A Gause.   

Abstract

Using a sandwich enzyme-linked immunosorbent assay (ELISA) we were able to detect a soluble form of the CD30 antigen (CD30s) in the supernatant of cell lines expressing membrane-bound CD30 and in T and B cells after transformation with human T-cell leukemia virus (HTLV-I) and Epstein-Barr-Virus (EBV). While CD30s was not found in 250 healthy controls, it was detected in the sera of patients with Hodgkin's disease (23/100), anaplastic large-cell (6/9), angioimmunoblastic (2/2) and one unclassified high-grade non-Hodgkin's lymphoma (NHL), as well as in 18/20 patients with acute adult T-cell leukemia (ATL, HTLV-I-positive). It was absent in a large number of patients with other high-grade NHL, all low-grade NHLs, acute or chronic leukemias and solid tumors. The only non-malignant disease with detectable levels of CD30s was infectious mononucleosis (9/10). The membrane-bound form of CD30 has a molecular weight of 120 kDa. Western blot analysis revealed that CD30s in the serum of patients has a molecular weight of 88 kDa, identical to the antigen released by cell lines in vitro. CD30s disappeared in all originally positive cases after successful treatment and reappeared in relapsing patients. Thus, CD30s may be useful as a specific marker for disease activity of certain types of lymphoma and ATL.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2159438     DOI: 10.1002/ijc.2910450515

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  9 in total

1.  Cell membrane-specific epitopes on CD30: Potentially superior targets for immunotherapy.

Authors:  Satoshi Nagata; Tomoko Ise; Masanori Onda; Kazuyasu Nakamura; Mitchell Ho; Andrew Raubitschek; Ira H Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-19       Impact factor: 11.205

2.  Elevated Serum Levels of sCD30 and IL6 and Detectable IL10 Precede Classical Hodgkin Lymphoma Diagnosis.

Authors:  Lynn I Levin; Elizabeth C Breen; Brenda M Birmann; Julie L Batista; Larry I Magpantay; Yuanzhang Li; Richard F Ambinder; Nancy E Mueller; Otoniel Martínez-Maza
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-03-24       Impact factor: 4.254

3.  Serum concentrations of sCD30 and sCD40L in patients with malignant bone tumours.

Authors:  Gerold Holzer; Thomas Pfandlsteiner; Harald Blahovec; Klemens Trieb; Rainer Kotz
Journal:  Wien Med Wochenschr       Date:  2003

4.  Effects of lymphocyte profile on development of EBV-induced lymphoma subtypes in humanized mice.

Authors:  Eun Kyung Lee; Eun Hye Joo; Kyung-A Song; Bongkum Choi; Miyoung Kim; Seok-Hyung Kim; Sung Joo Kim; Myung-Soo Kang
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-05       Impact factor: 11.205

5.  CD30 antigen in embryonal carcinoma and embryogenesis and release of the soluble molecule.

Authors:  U Latza; H D Foss; H Dürkop; F Eitelbach; K P Dieckmann; V Loy; M Unger; G Pizzolo; H Stein
Journal:  Am J Pathol       Date:  1995-02       Impact factor: 4.307

6.  Soluble interleukin-2 receptors (sIL-2R) in Hodgkin's disease: outcome and clinical implications.

Authors:  S Viviani; E Camerini; V Bonfante; A Santoro; M Balzarotti; M Fornier; L Devizzi; P Verderio; P Valagussa; G Bonadonna
Journal:  Br J Cancer       Date:  1998-03       Impact factor: 7.640

7.  Population differences in immune marker profiles associated with human T-lymphotropic virus type I infection in Japan and Jamaica.

Authors:  Brenda M Birmann; Elizabeth C Breen; Sherri Stuver; Beverly Cranston; Otoniel Martínez-Maza; Kerstin I Falk; Akihiko Okayama; Barrie Hanchard; Nancy Mueller; Michie Hisada
Journal:  Int J Cancer       Date:  2009-02-01       Impact factor: 7.396

Review 8.  Hodgkin's lymphoma and CD30 signal transduction.

Authors:  Ryouichi Horie; Masaaki Higashihara; Toshiki Watanabe
Journal:  Int J Hematol       Date:  2003-01       Impact factor: 2.490

9.  Elevated expression of CD30 in adult T-cell leukemia cell lines: possible role in constitutive NF-kappaB activation.

Authors:  Masaya Higuchi; Takehiro Matsuda; Naoki Mori; Yasuaki Yamada; Ryouichi Horie; Toshiki Watanabe; Masahiko Takahashi; Masayasu Oie; Masahiro Fujii
Journal:  Retrovirology       Date:  2005-05-06       Impact factor: 4.602

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.